Morning Star | Four Qiming Venture Partners Portfolio Companies Selected for S&P Global Sustainability Yearbook (China Edition) 2025
The Yearbook aims to identify and recognize Chinese companies that have demonstrated sustainable development advantages in industries such as biotechnology, healthcare, machinery and electrical equipment, automotive manufacturing, and communications equipment.
Recently, S&P Global released the Sustainability Yearbook (China Edition) 2025. The yearbook identifies and recognizes Chinese companies that have demonstrated sustainability advantages in sectors including biotech, healthcare, machinery and electrical equipment, automotive manufacturing, and communications equipment.
Four Qiming Venture Partners portfolio companies were selected for the yearbook: Gan & Lee Pharmaceuticals (603087.SH), Arrail Group (06639.HK), Zai Lab (NASDAQ: ZLAB, 09688.HK), and CanSino Biologics (688185.SH, 06185.HK). Among them, Gan & Lee Pharmaceuticals and Arrail Group were named Industry Top Improvers in biotech and healthcare, respectively.
Gan & Lee Pharmaceuticals, Arrail Group
Zai Lab, CanSino Biologics
Selected for
Sustainability Yearbook (China Edition) 2025
Gan & Lee Pharmaceuticals, Arrail Group
Named
Industry Top Improvers
Selection Criteria
- Sustainability Yearbook (China Edition) 2025
Yearbook membership and recognition levels are based on companies' 2024 Corporate Sustainability Assessment (CSA) scores. The selection process also reflects exclusion screening criteria. Recognition levels are calculated based on the scores of the best-performing companies in each industry, with exclusion criteria then applied. For the Industry Top Improver designation, a company's S&P Global CSA score must have improved by at least 5% year-over-year, representing the largest increase in its industry.
Dave Ernsberger and Mark Eramo, Co-Heads of Commodities at S&P Global, stated that "climate change is increasingly becoming an urgent priority for economic and social development. In our collective efforts to achieve this goal, we must recognize that the path is complex and multi-dimensional, requiring collaboration. The transition to a sustainable economy demands rethinking how we produce and consume, investing in innovative technologies, and cultivating resilient supply chains."
Source | S&P Global
Past Coverage
Qiming ESG | Qiming Venture Partners Named ESG Investment Special Contribution Institution for Consecutive Year Qiming Stars | Five Qiming Venture Partners Portfolio Companies Selected for 2024 China Listed Pharmaceutical Companies ESG Competitiveness List Qiming ESG | Qiming Venture Partners Selected as Top 10 Best Practices in Impact Investing at 2024 Guangming Awards
Founded in 2006, Qiming Venture Partners currently manages 11 USD funds and 7 RMB funds, with total assets under management reaching $9.5 billion. Since its inception, the firm has focused on investing in outstanding early- and growth-stage companies in the Technology and Consumer (T&C) and Healthcare sectors.
To date, Qiming Venture Partners has invested in over 580 high-growth innovative companies. More than 210 of these have gone public on the New York Stock Exchange, NASDAQ, Hong Kong Exchanges and Clearing, Shanghai Stock Exchange, and Shenzhen Stock Exchange, or exited through M&A and other means. Over 80 portfolio companies have become recognized unicorns or super-unicorns.
Many Qiming Venture Partners portfolio companies have grown into the most influential companies in their respective fields, including Xiaomi (01810.HK), Meituan (03690.HK), Bilibili (NASDAQ: BILI, 09626.HK), Zhihu (NYSE: ZH, 02390.HK), Roborock (688169.SH), UBTECH (09880.HK), WeRide (NASDAQ: WRD), Gan & Lee Pharmaceuticals (603087.SH), Tigermed (300347.SZ, 03347.HK), Zai Lab (NASDAQ: ZLAB, 09688.HK), CanSino Biologics (688185.SH, 06185.HK), Schrödinger (NASDAQ: SDGR), MicroPort EP MedTech (688617.SH), Sanyou Medical (688085.SH), Amoy Diagnostics (300685.SZ), Berry Genomics (000710.SZ), SinoCellTech (688520.SH), Yuanxin Technology, ClinChoice, Belief BioMed, Biren Technology, and others.